医药外包概念股悉数走高昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏

金吾资讯2025-11-12

金吾财讯 | 医药外包概念股悉数走高，截至发稿，昭衍新药(06127)跌5.24%，维亚生物(01873)涨3.77%，康龙化成(03759)涨3.59%，泰格医药(03347)涨2.72%，凯莱英(06821)涨2.55%，药明生物(02269)涨2.23%，药明康德(02359)涨1.97%。方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582482353?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-12 09:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582482353","market":"hk","top_or_hot":-1,"title":"医药外包概念股悉数走高 昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏","media":"金吾资讯","content":"<div>\n<p>金吾财讯 | 医药外包概念股悉数走高，截至发稿，昭衍新药(06127)跌5.24%，维亚生物(01873)涨3.77%，康龙化成(03759)涨3.59%，泰格医药(03347)涨2.72%，凯莱英(06821)涨2.55%，药明生物(02269)涨2.23%，药明康德(02359)涨1.97%。方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112095736a6f32e12&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药外包概念股悉数走高 昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药外包概念股悉数走高 昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-12 09:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112095736a6f32e12&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 医药外包概念股悉数走高，截至发稿，昭衍新药(06127)跌5.24%，维亚生物(01873)涨3.77%，康龙化成(03759)涨3.59%，泰格医药(03347)涨2.72%，凯莱英(06821)涨2.55%，药明生物(02269)涨2.23%，药明康德(02359)涨1.97%。方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112095736a6f32e12&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112095736a6f32e12&s=b","article_id":"2582482353","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112095736a6f32e12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582482353","pubTimestamp":1762912624,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"该行预期，资本市场融资活动恢复，创新药出海交易规模扩张，国内创新药研发需求回暖，加上美国进入降息周期，CXO企业下半年业绩表现有望复苏，预期已授权的创新药管线在海外的临床发展可成为创新药板块最重要催化剂。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","BK1141":"生命科学工具和服务","02269":"药明生物","BK1161":"生物科技","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1610":"ETF&股票定投概念","06821":"凯莱英","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","01873":"维亚生物","09939":"开拓药业-B","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","BK1521":"挪威政府全球养老基金持仓","03759":"康龙化成","BK1515":"抗疫概念","BK1574":"生物医药B类股","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","06127":"昭衍新药","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC"},"translate_title":"Pharmaceutical outsourcing concept stocks all rose, Zhaoyan New Drug fell 5.24%, institutions pointed out that the performance of CXO companies is expected to recover in the second half of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":0.9,"09939":1.5,"06127":1.5,"06821":0.9,"02269":0.9,"01873":0.9},"content_text":"金吾财讯 | 医药外包概念股悉数走高，截至发稿，昭衍新药(06127)跌5.24%，维亚生物(01873)涨3.77%，康龙化成(03759)涨3.59%，泰格医药(03347)涨2.72%，凯莱英(06821)涨2.55%，药明生物(02269)涨2.23%，药明康德(02359)涨1.97%。方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能强劲，坚定看好具备强出海能力的生物品类上游公司;CXO板块中，早研产业链具备极大发展空间，创新药出海具备历史性机遇。招银国际发布研报称，MSCI中国医疗指数年初至今累计升幅达59.5%，跑赢MSCI中国指数24%，至近期医药板块出现回调，10月初起回落约10%，认为部分股份估值较低，仍具吸引力。该行预期，资本市场融资活动恢复，创新药出海交易规模扩张，国内创新药研发需求回暖，加上美国进入降息周期，CXO企业下半年业绩表现有望复苏，预期已授权的创新药管线在海外的临床发展可成为创新药板块最重要催化剂。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582482353","isCrawlerRequest":true}

医药外包概念股悉数走高 昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏

精彩评论

医药外包概念股悉数走高昭衍新药跌5.24% 机构指CXO企业下半年业绩表现有望复苏